Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label single-arm study of U16 injection in relapsed/refractory B-cell non-Hodgkin lymphoma
CTR20230087Phase 2Active
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
- Start
- Mar 2023
- Countries
- 1
01
Overview
A Phase 2 trial of U16 in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), follicular lymphoma, transformed (t-FL), large-cell lymphoma, sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.. Started Mar 2023; status: active.
02
Drugs
U16
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma, transformed (t-FL)large-cell lymphoma
Beyond the preview
Go deeper on CTR20230087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230087.